Health-related resource use and costs in elderly adults with and without mild cognitive impairment
- PMID: 23414481
- PMCID: PMC3928966
- DOI: 10.1111/jgs.12132
Health-related resource use and costs in elderly adults with and without mild cognitive impairment
Abstract
Objectives: To assess differences in resource use and cost between older adults with and without mild cognitive impairment (MCI) over time.
Design: Multicenter, longitudinal study.
Setting: Sixty-eight Alzheimer's Disease Cooperative Study (ADCS) sites in the United States.
Participants: Two hundred fifty-nine individuals diagnosed with MCI and 107 cognitively normal elderly adults followed annually for 3 years.
Measurements: The Resource Use Instrument (RUI) was used to capture medical and nonmedical care use. Generalized linear latent and mixed models were used to estimate differences in resource use and costs in older adults with and without MCI after controlling for clinical and demographic characteristics.
Results: At baseline, average annual direct medical cost per person was substantially higher for participants with MCI ($6,499) than for those without ($2,969) P < .001). Informal care use was also substantially higher (33% vs 8.4%, P < .001). Results from multivariate analyses of longitudinal data show that, after controlling for participant and informant characteristics, direct medical costs were 44% higher for participants with MCI than for those without. Participants with MCI were almost five times as likely to use informal care as those without. Number of medical conditions and older age were associated with higher medical cost. Worse functional and cognitive status, older age, being married, and being female were associated with higher likelihood of informal care use. Having an adult child informant was associated with higher likelihood of using informal care.
Conclusion: The RUI captured differences in resource use and costs between individuals with and without MCI. Clinicians who care for individuals with MCI should address informal care needs early in the disease course.
© 2013, Copyright the Authors Journal compilation © 2013, The American Geriatrics Society.
Conflict of interest statement
Dr. Ferris serves as a consultant or advisory board member for Accera, Baxter, Bristol Myers Squibb, Eisai, Intellect Neurosciences, Janssen Alzheimer Immunotherapy, Elan, Eli Lilly, MedAvante, Merck, Merz, Neuronix, Pfizer, and United Biosource and receives research support from Baxter, Bristol Myers Squibb, Janssen Alzheimer Immunotherapy, Eisai, Eli Lilly, Medivation, Pfizer, and the NIA, NIH.
D. Aisen serves on a scientific advisory board for NeuroPhage and as a consultant to Elan Corporation, Wyeth, Eisai Inc., Bristol-Myers Squibb, Eli Lilly and Company, NeuroPhage, Merck & Co., Roche, Amgen, Abbott, Pfizer Inc, Novartis, Bayer, Astellas, Dainippon, Biomarin, Solvay, Otsuka, Daiichi, AstraZeneca, Janssen, Medivation, Inc., Theravance, Cardeus, and Anavex and receives research support from Pfizer Inc., Baxter International Inc., and the NIH (NIA U01-AG10483 (PI), NIA U01-AG024904 (Coordinating Center Director), NIA R01-AG030048 (PI), and R01-AG16381 (Co-I)).
Comment in
-
Accurate assessments of healthcare use along the course of cognitive decline.J Am Geriatr Soc. 2013 Mar;61(3):450-1. doi: 10.1111/jgs.12135. J Am Geriatr Soc. 2013. PMID: 23496179 No abstract available.
References
-
- Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194. - PubMed
-
- Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment—beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–246. - PubMed
-
- Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388. - PubMed
-
- Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr. 2004;16:129–140. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
